TLSI

SEC source: 0001415889-24-021958 · form4-08222024_120815.xml · derivative · entry 1

Hyveled Liselotte · CIK 0002015594 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2034-08-12

F1 · derivative.exercise_date: The shares subject to the option shall fully vest on the one-year anniversary of the grant date of August 13, 2024, provided that the shares subject to the option will in any case be fully vested on the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person's continued service with the Issuer.

SEC source: 0001415889-24-021962 · form4-08222024_120827.xml · derivative · entry 1

Wahlstrom Mats · CIK 0001459154 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2034-08-12

F1 · derivative.exercise_date: The shares subject to the option shall fully vest on the one-year anniversary of the grant date of August 13, 2024, provided that the shares subject to the option will in any case be fully vested on the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person's continued service with the Issuer.

SEC source: 0001415889-24-021946 · form4-08222024_120854.xml · derivative · entry 1

MATLIN DAVID J · CIK 0001251956 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2034-08-12

F1 · derivative.exercise_date: The shares subject to the option shall fully vest on the one-year anniversary of the grant date of August 13, 2024, provided that the shares subject to the option will in any case be fully vested on the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person's continued service with the Issuer.

SEC source: 0001415889-24-021938 · form4-08222024_120809.xml · derivative · entry 1

VON ESCHENBACH ANDREW C. · CIK 0001536529 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2034-08-12

F1 · derivative.exercise_date: The shares subject to the option shall fully vest on the one-year anniversary of the grant date of August 13, 2024, provided that the shares subject to the option will in any case be fully vested on the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person's continued service with the Issuer.

SEC source: 0001415889-24-021950 · form4-08222024_120845.xml · derivative · entry 1

Martin George Kelly · CIK 0001982607 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2034-08-12

F1 · derivative.exercise_date: The shares subject to the option shall fully vest on the one-year anniversary of the grant date of August 13, 2024, provided that the shares subject to the option will in any case be fully vested on the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person's continued service with the Issuer.

SEC source: 0001415889-24-021943 · form4-08222024_120829.xml · derivative · entry 1

Desai Arjun JJ · CIK 0001982985 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2034-08-12

F1 · derivative.exercise_date: The shares subject to the option shall fully vest on the one-year anniversary of the grant date of August 13, 2024, provided that the shares subject to the option will in any case be fully vested on the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person's continued service with the Issuer.

SEC source: 0001415889-24-021940 · form4-08222024_120848.xml · derivative · entry 1

Singhal Anil K. · CIK 0001982984 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2034-08-12

F1 · derivative.exercise_date: The shares subject to the option shall fully vest on the one-year anniversary of the grant date of August 13, 2024, provided that the shares subject to the option will in any case be fully vested on the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person's continued service with the Issuer.

SEC source: 0001415889-24-019061 · form4-07032024_120751.xml · derivative · entry 2

Desai Arjun JJ · CIK 0001982985 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 246,667 shares

Expires not disclosed

F3 · derivative.exercise_price: Represents Warrants received as a pro rata distribution for no consideration from MedTech Acquisition Sponsor LLC ("Sponsor") in accordance with the terms of the Sponsor's limited liability company agreement.

F1 · price: As previously disclosed, on May 24, 2024, TriSalus Life Sciences, Inc. (the "Issuer"), announced the commencement of its offer (the "Issuer Tender Offer") to all holders of each class of certain outstanding warrants (the "Warrants"), consisting of (a) the Issuer's publicly-traded Warrants currently listed on the Nasdaq Global Market under the symbol "TLSIW", (b) certain Warrants issued in a private placement transaction occurring simultaneously with the closing of the initial public offering of the Issuer and (c) certain Warrants issued for working capital requirements and payment of certain expenses of the Issuer, each identified in the Prospectus/Offer to Exchange that forms a part of the Issuer's Registration Statement on Form S-4 (Registration No. 333- 279691), filed with the Securities and Exchange Commission on May 24, 2024, to receive 0.3 shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), [continued on footnote 2]

F2 · price: [continued from footnote 1] in exchange for each Warrant tendered by the holder and exchanged pursuant to the Issuer Tender Offer. Pursuant to the Issuer Tender Offer, the Reporting Person tendered 246,667 Warrants in exchange for 74,000 shares of Common Stock.

F4 · derivative.expiration_date: The Warrants expire on August 9, 2028, or earlier upon redemption or liquidation.

SEC source: 0001415889-24-019061 · form4-07032024_120751.xml · nonDerivative · entry 1

Desai Arjun JJ · CIK 0001982985 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 277,127

F1 · price: As previously disclosed, on May 24, 2024, TriSalus Life Sciences, Inc. (the "Issuer"), announced the commencement of its offer (the "Issuer Tender Offer") to all holders of each class of certain outstanding warrants (the "Warrants"), consisting of (a) the Issuer's publicly-traded Warrants currently listed on the Nasdaq Global Market under the symbol "TLSIW", (b) certain Warrants issued in a private placement transaction occurring simultaneously with the closing of the initial public offering of the Issuer and (c) certain Warrants issued for working capital requirements and payment of certain expenses of the Issuer, each identified in the Prospectus/Offer to Exchange that forms a part of the Issuer's Registration Statement on Form S-4 (Registration No. 333- 279691), filed with the Securities and Exchange Commission on May 24, 2024, to receive 0.3 shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), [continued on footnote 2]

F2 · price: [continued from footnote 1] in exchange for each Warrant tendered by the holder and exchanged pursuant to the Issuer Tender Offer. Pursuant to the Issuer Tender Offer, the Reporting Person tendered 246,667 Warrants in exchange for 74,000 shares of Common Stock.

SEC source: 0001628280-26-046501 · wk-form5_1782936102.xml · nonDerivative · entry 1

Marshak Richard · CIK 0001982638 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,530

F1 · shares: Represents shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3.

SEC source: 0001415889-24-015617 · form4-06052024_090658.xml · derivative · entry 2

VON ESCHENBACH ANDREW C. · CIK 0001536529 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · The Vons Living Trust U/T/A 4/3/2024 dated 4/3/2024

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2033-08-09

F1 · kind: The Reporting Person transferred this option to The Vons Living Trust U/T/A 4/3/2024 dated 4/3/2024, Andrew von Eschenbach and Madelyn Giancaterino von Eschenbach, Co-Trustees (the "Trust") for no consideration. The Reporting Person and his spouse are co-trustees of the Trust, and the Reporting Person is the sole beneficiary of the Trust. The Reporting Person remains the beneficial owner of the securities held by the Trust.

F2 · derivative.exercise_date: The shares subject to this stock option vest in three equal annual installments from the vesting commencement date of August 10, 2023, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

F1 · ownership.direct: The Reporting Person transferred this option to The Vons Living Trust U/T/A 4/3/2024 dated 4/3/2024, Andrew von Eschenbach and Madelyn Giancaterino von Eschenbach, Co-Trustees (the "Trust") for no consideration. The Reporting Person and his spouse are co-trustees of the Trust, and the Reporting Person is the sole beneficiary of the Trust. The Reporting Person remains the beneficial owner of the securities held by the Trust.

SEC source: 0001415889-24-015617 · form4-06052024_090658.xml · derivative · entry 1

VON ESCHENBACH ANDREW C. · CIK 0001536529 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 35,000 shares

Expires 2033-08-09

F1 · kind: The Reporting Person transferred this option to The Vons Living Trust U/T/A 4/3/2024 dated 4/3/2024, Andrew von Eschenbach and Madelyn Giancaterino von Eschenbach, Co-Trustees (the "Trust") for no consideration. The Reporting Person and his spouse are co-trustees of the Trust, and the Reporting Person is the sole beneficiary of the Trust. The Reporting Person remains the beneficial owner of the securities held by the Trust.

F2 · derivative.exercise_date: The shares subject to this stock option vest in three equal annual installments from the vesting commencement date of August 10, 2023, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

SEC source: 0001415889-24-012501 · form4-05072024_090508.xml · derivative · entry 1

Hyveled Liselotte · CIK 0002015594 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2034-05-05

F1 · derivative.exercise_date: The shares subject to this stock option vest in three equal annual installments from the vesting commencement date of May 6, 2024, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

SEC source: 0001415889-24-003821 · form4-02142024_110233.xml · derivative · entry 2

Szela Mary T · CIK 0001410289 · Director · CEO AND PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 288,750

Underlying: Common Stock · 288,750 shares

Expires 2034-02-12

F2 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the vesting commencement date of February 13, 2024, and 1/36th of the remaining shares shall vest each month thereafter, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

SEC source: 0001415889-24-003821 · form4-02142024_110233.xml · nonDerivative · entry 1

Szela Mary T · CIK 0001410289 · Director · CEO AND PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 364,862

F1 · shares: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award vest in four equal annual installments commencing on February 13, 2024, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

SEC source: 0001410289-25-000006 · wk-form4_1764104104.xml · nonDerivative · entry 1

Szela Mary T · CIK 0001410289 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 317,802

F1 · shares: Represents the granting of Performance Stock Units (PSUs) upon achieving or exceeding $50 million of revenue over any 12 consecutive calendar month period ending on or before February 28, 2027. The PSUs vest immediately upon achieving the performance requirement, subject to the continued employment through each respective vesting date.

SEC source: 0001415889-24-003807 · form4-02142024_110246.xml · derivative · entry 2

Devlin Jodi · CIK 0001992151 · PRESIDENT, COMMERC. OPERATIONS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,000

Underlying: Common Stock · 105,000 shares

Expires 2034-02-11

F2 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the vesting commencement date of February 12, 2024, and 1/36th of the remaining shares shall vest each month thereafter, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

SEC source: 0001415889-24-003807 · form4-02142024_110246.xml · nonDerivative · entry 1

Devlin Jodi · CIK 0001992151 · PRESIDENT, COMMERC. OPERATIONS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,500

F1 · shares: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award vest in four equal annual installments commencing on February 12, 2024, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

SEC source: 0001415889-24-003799 · form4-02142024_110211.xml · derivative · entry 2

Katz Steven C · CIK 0001983649 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,000

Underlying: Common Stock · 105,000 shares

Expires 2034-02-11

F2 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the vesting commencement date of February 12, 2024, and 1/36th of the remaining shares shall vest each month thereafter, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

SEC source: 0001415889-24-003799 · form4-02142024_110211.xml · nonDerivative · entry 1

Katz Steven C · CIK 0001983649 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,587

F1 · shares: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award vest in four equal annual installments commencing on February 12, 2024, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

SEC source: 0001415889-24-003811 · form4-02142024_110203.xml · derivative · entry 2

Stevens Jennifer · CIK 0001982621 · CHIEF REGULATORY OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,750

Underlying: Common Stock · 63,750 shares

Expires 2034-02-11

F2 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the vesting commencement date of February 12, 2024, and 1/36th of the remaining shares shall vest each month thereafter, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

SEC source: 0001415889-24-003811 · form4-02142024_110203.xml · nonDerivative · entry 1

Stevens Jennifer · CIK 0001982621 · CHIEF REGULATORY OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,783

F1 · shares: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award vest in four equal annual installments commencing on February 12, 2024, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

SEC source: 0001415889-24-003817 · form4-02142024_110206.xml · derivative · entry 2

Marshak Richard · CIK 0001982638 · SR.VP, CORP. DEV. & STRATEGY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,750

Underlying: Common Stock · 63,750 shares

Expires 2034-02-11

F2 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the vesting commencement date of February 12, 2024, and 1/36th of the remaining shares shall vest each month thereafter, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

SEC source: 0001415889-24-003817 · form4-02142024_110206.xml · nonDerivative · entry 1

Marshak Richard · CIK 0001982638 · SR.VP, CORP. DEV. & STRATEGY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,251

F1 · shares: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award vest in four equal annual installments commencing on February 12, 2024, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

SEC source: 0001415889-24-003806 · form4-02142024_110255.xml · derivative · entry 4

Murphy Sean · CIK 0001685042 · Director · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,000

Underlying: Common Stock · 105,000 shares

Expires 2034-02-11

F3 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the vesting commencement date of February 12, 2024, and 1/36th of the remaining shares shall vest each month thereafter, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

SEC source: 0001415889-24-003806 · form4-02142024_110255.xml · nonDerivative · entry 1

Murphy Sean · CIK 0001685042 · Director · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,788

F1 · shares: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award vest in four equal annual installments commencing on February 12, 2024, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

SEC source: 0001415889-24-003815 · form4-02142024_110248.xml · derivative · entry 2

Cox Bryan F. · CIK 0001981787 · CHIEF SCIENTIFIC & MANUFACT.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,750

Underlying: Common Stock · 63,750 shares

Expires 2034-02-11

F2 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the vesting commencement date of February 12, 2024, and 1/36th of the remaining shares shall vest each month thereafter, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

SEC source: 0001415889-24-003815 · form4-02142024_110248.xml · nonDerivative · entry 1

Cox Bryan F. · CIK 0001981787 · CHIEF SCIENTIFIC & MANUFACT.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,696

F1 · shares: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award vest in four equal annual installments commencing on February 12, 2024, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

SEC source: 0001415889-24-001819 · form4-01252024_100125.xml · derivative · entry 1

Marshak Richard · CIK 0001982638 · SR.VP, CORP. DEV. & STRATEGY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2034-01-23

F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date of January 24, 2024, and 1/36th of the remaining shares shall vest each month thereafter, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

SEC source: 0001415889-24-001820 · form4-01252024_100149.xml · derivative · entry 1

Murphy Sean · CIK 0001685042 · Director · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2034-01-23

F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date of January 24, 2024, and 1/36th of the remaining shares shall vest each month thereafter, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

SEC source: 0001209191-23-047894 · doc4.xml · derivative · entry 1

Devlin Jodi · CIK 0001992151 · President, Therapeutics

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 195,000

Underlying: Common Stock · 195,000 shares

Expires 2033-08-29

F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the vesting commencement date of August 28, 2023, and 1/36th of the remaining shares shall vest each month thereafter on the same day of the month as the vesting commencement date.

SEC source: 0001209191-23-045877 · doc4.xml · derivative · entry 1

Szela Mary T · CIK 0001410289 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 172,500

Underlying: Common Stock · 172,500 shares

Expires 2033-08-13

F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date of August 10, 2023, and 1/36th of the remaining shares shall vest each month thereafter, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

SEC source: 0001209191-23-045720 · doc4.xml · derivative · entry 1

Katz Steven C · CIK 0001983649 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,500

Underlying: Common Stock · 62,500 shares

Expires 2033-08-10

F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date of August 10, 2023, and 1/36th of the remaining shares shall vest each month thereafter, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

SEC source: 0001209191-23-045733 · doc4.xml · derivative · entry 1

Stevens Jennifer · CIK 0001982621 · Chief Regulatory Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2033-08-10

F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date of August 10, 2023, and 1/36th of the remaining shares shall vest each month thereafter, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

SEC source: 0001209191-23-045725 · doc4.xml · derivative · entry 1

Marshak Richard · CIK 0001982638 · Sr.VP, Corp. Dev. & Strategy

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2033-08-10

F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date of August 10, 2023, and 1/36th of the remaining shares shall vest each month thereafter, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

SEC source: 0001209191-23-045730 · doc4.xml · derivative · entry 1

Murphy Sean · CIK 0001685042 · Director · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,500

Underlying: Common Stock · 62,500 shares

Expires 2033-08-10

F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date of August 10, 2023, and 1/36th of the remaining shares shall vest each month thereafter, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

SEC source: 0001209191-23-045716 · doc4.xml · derivative · entry 1

Cox Bryan F. · CIK 0001981787 · Chief Scientific & Manufact.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2033-08-10

F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date of August 10, 2023, and 1/36th of the remaining shares shall vest each month thereafter, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

SEC source: 0001209191-23-045690 · doc4.xml · derivative · entry 1

HICKS KERRY R · CIK 0001110473 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2033-08-09

F1 · derivative.exercise_date: The shares subject to this stock option vest in three equal annual installments from the vesting commencement date of August 10, 2023, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

SEC source: 0001209191-23-045700 · doc4.xml · derivative · entry 1

Wahlstrom Mats · CIK 0001459154 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2033-08-09

F1 · derivative.exercise_date: The shares subject to this stock option vest in three equal annual installments from the vesting commencement date of August 10, 2023, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

SEC source: 0001209191-23-045693 · doc4.xml · derivative · entry 4

MATLIN DAVID J · CIK 0001251956 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires not disclosed

F5 · derivative.exercise_date: The Series A Convertible Preferred Stock ("Preferred Stock") is convertible, in whole or in part, into 100,000 shares of Common Stock of the Issuer (based on an initial conversion price of $10.00 per share, which is subject to adjustment upon the occurrence of certain events, the "Conversion Price") at any time, at the Reporting Person's election. The number of shares of the Issuer's Common Stock received per share of Preferred Stock upon conversion equals the sum of (A) $10.00 (as adjusted upon the occurrence of certain events) and (B) any accrued, unpaid annual dividends, divided by the Conversion Price, with cash in-lieu of fractional shares. All then outstanding shares of Preferred Stock are automatically converted into shares of the Issuer's Common Stock on August 10, 2027.

F5 · derivative.expiration_date: The Series A Convertible Preferred Stock ("Preferred Stock") is convertible, in whole or in part, into 100,000 shares of Common Stock of the Issuer (based on an initial conversion price of $10.00 per share, which is subject to adjustment upon the occurrence of certain events, the "Conversion Price") at any time, at the Reporting Person's election. The number of shares of the Issuer's Common Stock received per share of Preferred Stock upon conversion equals the sum of (A) $10.00 (as adjusted upon the occurrence of certain events) and (B) any accrued, unpaid annual dividends, divided by the Conversion Price, with cash in-lieu of fractional shares. All then outstanding shares of Preferred Stock are automatically converted into shares of the Issuer's Common Stock on August 10, 2027.

SEC source: 0001209191-23-045693 · doc4.xml · derivative · entry 3

MATLIN DAVID J · CIK 0001251956 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2023-08-08

F4 · derivative.exercise_date: The shares subject to this stock option vest in three equal annual installments from the vesting commencement date of August 10, 2023, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

SEC source: 0001209191-23-045693 · doc4.xml · derivative · entry 2

MATLIN DAVID J · CIK 0001251956 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,240,518

Underlying: Common Stock · 1,240,518 shares

Expires not disclosed

F2 · kind: Represents warrants received as a pro rata distribution for no consideration from the Sponsor in accordance with the terms of the Sponsor's limited liability company agreement.

F2 · price: Represents warrants received as a pro rata distribution for no consideration from the Sponsor in accordance with the terms of the Sponsor's limited liability company agreement.

F3 · derivative.expiration_date: The redeemable warrants expire on August 10, 2028, or earlier upon redemption or liquidation.

F2 · balance_after: Represents warrants received as a pro rata distribution for no consideration from the Sponsor in accordance with the terms of the Sponsor's limited liability company agreement.

SEC source: 0001209191-23-045693 · doc4.xml · nonDerivative · entry 1

MATLIN DAVID J · CIK 0001251956 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 931,904

F1 · kind: Represents shares of Common Stock received as a pro rata distribution for no consideration from MedTech Acquisition Sponsor LLC ("Sponsor") in accordance with the terms of the Sponsor's limited liability company agreement. In prior reports, the Reporting Person reported beneficial ownership of 6,250,000 shares of Issuer's Common Stock held by the Sponsor, of which the Reporting Person is a managing member.

F1 · price: Represents shares of Common Stock received as a pro rata distribution for no consideration from MedTech Acquisition Sponsor LLC ("Sponsor") in accordance with the terms of the Sponsor's limited liability company agreement. In prior reports, the Reporting Person reported beneficial ownership of 6,250,000 shares of Issuer's Common Stock held by the Sponsor, of which the Reporting Person is a managing member.

F1 · balance_after: Represents shares of Common Stock received as a pro rata distribution for no consideration from MedTech Acquisition Sponsor LLC ("Sponsor") in accordance with the terms of the Sponsor's limited liability company agreement. In prior reports, the Reporting Person reported beneficial ownership of 6,250,000 shares of Issuer's Common Stock held by the Sponsor, of which the Reporting Person is a managing member.

SEC source: 0001209191-23-045697 · doc4.xml · derivative · entry 1

VON ESCHENBACH ANDREW C. · CIK 0001536529 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2033-08-09

F1 · derivative.exercise_date: The shares subject to this stock option vest in three equal annual installments from the vesting commencement date of August 10, 2023, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

SEC source: 0001209191-23-045695 · doc4.xml · derivative · entry 1

Singhal Anil K. · CIK 0001982984 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2033-08-09

F1 · derivative.exercise_date: The shares subject to this stock option vest in three equal annual installments from the vesting commencement date of August 10, 2023, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

SEC source: 0001209191-23-045692 · doc4.xml · derivative · entry 1

Martin George Kelly · CIK 0001982607 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2033-08-09

F1 · derivative.exercise_date: The shares subject to this stock option vest in three equal annual installments from the vesting commencement date of August 10, 2023, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

SEC source: 0001209191-23-045685 · doc4.xml · derivative · entry 1

Desai Arjun JJ · CIK 0001982985 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2033-08-09

F1 · derivative.exercise_date: The shares subject to this stock option vest in three equal annual installments from the vesting commencement date of August 10, 2023, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

SEC source: 0001104659-23-075256 · tm2319584-1_4seq1.xml · derivative · entry 2

MedTech Acquisition Sponsor LLC · CIK 0001826760 · 10% owner

Dewey Christopher C · CIK 0001385015 · 10% owner

MATLIN DAVID J · CIK 0001251956 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1

Underlying: Class A Common Stock · 6,249,999 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The shares of Class B common stock, par value $0.0001 per share ("Class B Common Stock"), of the issuer are convertible into an equal number of shares of Class A common stock, par value $0.0001 per share ("Class A Common Stock"), of the issuer. On June 26, 2023, MedTech Acquisition Sponsor LLC (the "Sponsor") elected to convert 6,249,999 shares of their Class B Common Stock into an equal number of Class A Common Stock.

F1 · kind: The shares of Class B common stock, par value $0.0001 per share ("Class B Common Stock"), of the issuer are convertible into an equal number of shares of Class A common stock, par value $0.0001 per share ("Class A Common Stock"), of the issuer. On June 26, 2023, MedTech Acquisition Sponsor LLC (the "Sponsor") elected to convert 6,249,999 shares of their Class B Common Stock into an equal number of Class A Common Stock.

F1 · price: The shares of Class B common stock, par value $0.0001 per share ("Class B Common Stock"), of the issuer are convertible into an equal number of shares of Class A common stock, par value $0.0001 per share ("Class A Common Stock"), of the issuer. On June 26, 2023, MedTech Acquisition Sponsor LLC (the "Sponsor") elected to convert 6,249,999 shares of their Class B Common Stock into an equal number of Class A Common Stock.

F1 · derivative.exercise_date: The shares of Class B common stock, par value $0.0001 per share ("Class B Common Stock"), of the issuer are convertible into an equal number of shares of Class A common stock, par value $0.0001 per share ("Class A Common Stock"), of the issuer. On June 26, 2023, MedTech Acquisition Sponsor LLC (the "Sponsor") elected to convert 6,249,999 shares of their Class B Common Stock into an equal number of Class A Common Stock.

F1 · derivative.expiration_date: The shares of Class B common stock, par value $0.0001 per share ("Class B Common Stock"), of the issuer are convertible into an equal number of shares of Class A common stock, par value $0.0001 per share ("Class A Common Stock"), of the issuer. On June 26, 2023, MedTech Acquisition Sponsor LLC (the "Sponsor") elected to convert 6,249,999 shares of their Class B Common Stock into an equal number of Class A Common Stock.

F2 · ownership.direct: The Sponsor is the record holder of the securities reported herein. Christopher C. Dewey and David J. Matlin are managing members of the Sponsor. By virtue of this relationship, each of these individuals may be deemed to share beneficial ownership of the securities held of record by the Sponsor. Each of them disclaims any such beneficial ownership except to the extent of their pecuniary interest therein.

SEC source: 0001104659-23-075256 · tm2319584-1_4seq1.xml · nonDerivative · entry 1

MedTech Acquisition Sponsor LLC · CIK 0001826760 · 10% owner

Dewey Christopher C · CIK 0001385015 · 10% owner

MATLIN DAVID J · CIK 0001251956 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,249,999

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The shares of Class B common stock, par value $0.0001 per share ("Class B Common Stock"), of the issuer are convertible into an equal number of shares of Class A common stock, par value $0.0001 per share ("Class A Common Stock"), of the issuer. On June 26, 2023, MedTech Acquisition Sponsor LLC (the "Sponsor") elected to convert 6,249,999 shares of their Class B Common Stock into an equal number of Class A Common Stock.

F1 · price: The shares of Class B common stock, par value $0.0001 per share ("Class B Common Stock"), of the issuer are convertible into an equal number of shares of Class A common stock, par value $0.0001 per share ("Class A Common Stock"), of the issuer. On June 26, 2023, MedTech Acquisition Sponsor LLC (the "Sponsor") elected to convert 6,249,999 shares of their Class B Common Stock into an equal number of Class A Common Stock.

F2 · ownership.direct: The Sponsor is the record holder of the securities reported herein. Christopher C. Dewey and David J. Matlin are managing members of the Sponsor. By virtue of this relationship, each of these individuals may be deemed to share beneficial ownership of the securities held of record by the Sponsor. Each of them disclaims any such beneficial ownership except to the extent of their pecuniary interest therein.

SEC source: 0001140361-23-029912 · form4.xml · nonDerivative · entry 10

Magnetar Financial LLC · CIK 0001352851 · 10% owner

Magnetar Capital Partners LP · CIK 0001353085 · 10% owner

Supernova Management LLC · CIK 0001368026 · 10% owner

Snyderman David J. · CIK 0001953511 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 16,668

F14 · kind: The Reporting Persons elected to redeem these shares of the Issuer's Class A Common Stock for cash in connection with the Issuer's special meeting of stockholders on June 12, 2023.

F1 · ownership.nature: Magnetar Financial LLC ("Magnetar Financial") serves as investment manager of each of (1) Magnetar Constellation Fund II Ltd, Magnetar Constellation Master Fund, Ltd, Magnetar Healthcare Master Fund Ltd, Magnetar SC Fund Ltd, Magnetar Xing He Master Fund Ltd, and Purpose Alternative Credit Fund Ltd, all of which are Cayman Islands exempted companies, (2) Magnetar Structured Credit Fund, LP, a Delaware limited partnership, (3) Magnetar Lake Credit Fund LLC and Purpose Alternative Credit Fund - T LLC, all of which are Delaware limited liability companies, and (4) three separately managed accounts (collectively, the "Magnetar Funds").

F2 · ownership.nature: Magnetar Capital Partners LP ("Magnetar Capital Partners"), a Delaware limited partnership, is the sole member and parent holding company of Magnetar Financial. Supernova Management LLC ("Supernova Management"), a Delaware limited liability company, is the general partner of Magnetar Capital Partners. The manager of Supernova Management is David J. Snyderman, a citizen of the United States of America.

F3 · ownership.nature: Each of the Magnetar Funds, Magnetar Financial, Magnetar Capital Partners, Supernova Management and David J. Snyderman disclaims beneficial ownership of these shares of the Issuer's Class A Common Stock.

F13 · ownership.nature: These securities are held directly by Purpose Alternative Credit Fund - T LLC.